前往化源商城

Immunology 2015-07-01

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Emmanouil Papasavvas, Andrea Foulkes, Xiangfan Yin, Jocelin Joseph, Brian Ross, Livio Azzoni, Jay R Kostman, Karam Mounzer, Jane Shull, Luis J Montaner

文献索引:Immunology 145 , 380-90, (2015)

全文:HTML全文

摘要

The identification of immune correlates of HIV control is important for the design of immunotherapies that could support cure or antiretroviral therapy (ART) intensification-related strategies. ART interruptions may facilitate this task through exposure of an ART partially reconstituted immune system to endogenous virus. We investigated the relationship between set-point plasma HIV viral load (VL) during an ART interruption and innate/adaptive parameters before or after interruption. Dendritic cell (DC), natural killer (NK) cell and HIV Gag p55-specific T-cell functional responses were measured in paired cryopreserved peripheral blood mononuclear cells obtained at the beginning (on ART) and at set-point of an open-ended interruption from 31 ART-suppressed chronically HIV-1(+) patients. Spearman correlation and linear regression modeling were used. Frequencies of plasmacytoid DC (pDC), and HIV Gag p55-specific CD3(+)  CD4(-)  perforin(+)  IFN-γ(+) cells at the beginning of interruption associated negatively with set-point plasma VL. Inclusion of both variables with interaction into a model resulted in the best fit (adjusted R(2)  = 0·6874). Frequencies of pDC or HIV Gag p55-specific CD3(+)  CD4(-)  CSFE(lo)  CD107a(+) cells at set-point associated negatively with set-point plasma VL. The dual contribution of pDC and anti-HIV T-cell responses to viral control, supported by our models, suggests that these variables may serve as immune correlates of viral control and could be integrated in cure or ART-intensification strategies. © 2015 John Wiley & Sons Ltd.

相关化合物

结构式 名称/CAS号 全部文献
1-硫代癸烷 结构式 1-硫代癸烷
CAS:143-10-2
布雷菲德菌素A 结构式 布雷菲德菌素A
CAS:20350-15-6
5-(((2,5-二氧吡咯烷-1-基)氧基)羰基)-3-羰基-3H-螺-[异苯并呋喃-1,9'-氧杂蒽]-3',6'-二基 二乙酸酯 结构式 5-(((2,5-二氧吡咯烷-1-基)氧基)羰基)-3-羰基-3H-螺-[异苯并呋喃-1,9'-氧杂蒽]-3',6'-二基 二乙酸酯
CAS:150206-05-6
月桂酸乙烯酯 结构式 月桂酸乙烯酯
CAS:2146-71-6
5(6)-羧基二乙酸荧光素琥珀酰亚胺酯(CFDA) 结构式 5(6)-羧基二乙酸荧光素琥珀酰亚胺酯(CFDA)
CAS:150347-59-4